ChiCTR1900028458 版本V1.0 版本创建时间2019/12/22 15:38:57 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900028458 

最近更新日期:

Date of Last Refreshed on:

2019-12-22 15:37:03 

注册时间:

Date of Registration:

2019-12-22 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

宫颈高危型HPV感染对宫颈、阴道分泌物菌群构成及宫颈鳞状上皮免疫状态的影响

Public title:

The effect of high risk cervical HPV infection on the microbiota of cervical and vaginal secretions and the immune status of cervical squamous epithelium

注册题目简写:

English Acronym:

研究课题的正式科学名称:

宫颈高危型HPV感染对宫颈、阴道分泌物菌群构成及宫颈鳞状上皮免疫状态的影响

Scientific title:

The effect of high risk cervical HPV infection on the microbiota of cervical and vaginal secretions and the immune status of cervical squamous epithelium

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张展 

研究负责人:

毕蕙, 刘朝晖 

Applicant:

Zhang zhan 

Study leader:

Bi Hui, Liu Zhaohui 

申请注册联系人电话:

Applicant telephone:

+86 13001112881

研究负责人电话:

Study leader's telephone:

+86 15652335331

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1206333073@qq.com

研究负责人电子邮件:

Study leader's E-mail:

23662161@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区姚家园路251号

研究负责人通讯地址:

北京市朝阳区姚家园路251号

Applicant address:

251 Yaojiayuan Road, Chaoyang District, Beijing

Study leader's address:

251 Yaojiayuan Road, Chaoyang District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京妇产医院

Applicant's institution:

Beijing Obstetrics and Gynecology Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学附属北京妇产医院

Affiliation of the Leader:

Beijing Obstetrics and Gynecology Hospital, Capital Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2017【1372】

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

北京大学第一医院临床研究伦理委员会

Name of the ethic committee:

Clinical Research Ethics Committee of Peking University First Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2017-08-04 00:00:00

伦理委员会联系人:

朱赛楠

Contact Name of the ethic committee:

Zhu Sainan

伦理委员会联系地址:

北京市西城区西什库大街8号

Contact Address of the ethic committee:

8 Xishiku Road, Xicheng District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京大学第一医院

Primary sponsor:

Peking University First Hospital

研究实施负责(组长)单位地址:

北京市西城区西安门大街1号

Primary sponsor's address:

1 Xi'anmen Road, Xicheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijng

City:

单位(医院):

北京大学第一医院

具体地址:

西城区西安门大街1号

Institution
hospital:

Peking University First Hospital

Address:

1 Xi'anmen Road, Xicheng District

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京妇产医院

具体地址:

朝阳区姚家园路251号

Institution
hospital:

Beijing Obstetrics and Gynecology Hospital, Capital Medical University

Address:

251 Yao-Jia-Yuan Road, Chaoyang District

经费或物资来源:

Source(s) of funding:

No

Target disease:

HPV infection

Target disease code:

研究类型:

基础科学研究

Study type:

Basic Science

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

了解宫颈高危型HPV感染女性患者阴道及宫颈菌群的情况及宫颈鳞状上皮天然免疫状态。  

Objectives of Study:

This topic will focus on the lower genital microenvironment of hrHPV infected women, analyze their vaginal and cervical microbiota, understand innate immune status of cervical squamous epithelium.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

① 年龄≥18岁,未绝经,有性生活者;
② 知情同意可配合研究;
③ 高危HPV感染。

Inclusion criteria

1. Aged >=18 years, not menopause, have sexual life;
2. Informed consent;
3. High-risk HPV infection.

排除标准:

① 妊娠期、哺乳期和月经期;
② 使用激素类药物避孕或激素替代治疗者;
③ 7天内应用抗生素,3天内性生活或阴道冲洗。

Exclusion criteria:

1. Pregnancy, lactation or menstruation period;
2. Long time use of glucocorticoids or immunosuppressants;
3. Use antibiotics within 7 days, have sexual life or vaginal douching within 3 days.

研究实施时间:

Study execute time:

From 2020-01-01 00:00:00 To 2020-03-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-01-01 00:00:00 To 2020-03-01 00:00:00  

干预措施:

Interventions:

组别:

HPV高危型阳性女性

样本量:

50

Group:

hrHPV infected women

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

TCT及HPV阴性女性组

样本量:

50

Group:

women with normal TCT and non-HPR infection

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

北京大学第一医院 

单位级别:

三甲医院 

Institution
hospital:

Peking University First Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

阴道菌群

指标类型:

主要指标

Outcome:

vaginal microbiota

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

宫颈菌群

指标类型:

主要指标

Outcome:

cervical microbiota

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

免疫因子

指标类型:

次要指标

Outcome:

immune factors

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

阴道分泌物

组织:

Sample Name:

vaginal discharge

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

宫颈分泌物

组织:

Sample Name:

cervical discharge

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

宫颈上皮

组织:

宫颈

Sample Name:

cervical epithelium

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

Resman, http://www.medresman.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan, http://www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

ResMan

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

ResMan

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-12-22 15:37:03